Could the CSL share price reach $200 in 2027?

The CSL Ltd (ASX: CSL) share price has staged a strong recovery from its $90 low and is now trading around $136.69.

Sentiment towards the healthcare giant has clearly improved, although there is still plenty of ground to make up after a difficult period.

Could the recovery eventually take CSL shares back to $200 in 2027?

What would $200 actually mean?

According to CommSec, the consensus earnings per share estimate currently stands at $8.30 for FY27.

At a $200 share price, CSL would therefore be trading on a P/E ratio of roughly 24 times forecast FY27 earnings.

I don't think that multiple is unreasonable for a high-quality global healthcare company if investors become confident that earnings growth is returning.

For some context, I recently highlighted that US pharmaceutical giant Eli Lilly (NYSE: LLY) trades at around 30 times forward earnings. CSL does not need to command that sort of multiple to reach $200.

A forward P/E ratio of 24 times on FY27 earnings would put the shares at approximately $199.20.

The bigger question is whether CSL can do enough over the next year to convince investors that it deserves such a re-rating.

What needs to go right?

CSL still has some work to do.

Its May trading update showed that underlying demand for immunoglobulin remained healthy, growing at a mid-to-high-single-digit rate. CSL also expects Behring revenue growth in the second half of FY26, supported by underlying demand and its operational improvement initiatives.

I think a sustained improvement in Behring would go a long way towards rebuilding confidence.

Investors will also want to see progress with albumin in China. CSL said volumes had stabilised and its market share was expanding in May, although weaker market conditions had weighed on the business.

Then there is Vifor. CSL expects substantial impairments across FY26 and FY27, while competition in iron has also created pressure. Improvements here could help with sentiment.

The appointment of a permanent chief executive could help as well. CSL said in May that its global CEO search was progressing, and I think greater leadership certainty could be another step towards restoring investor confidence.

The FY26 result this week should provide the next major indication of how quickly that recovery is progressing.

Could it happen in 2027?

I think $200 is possible, although I would stop short of calling it likely.

From around $136.69, CSL shares would need to rise approximately 46% to reach that level.

Consensus is also only expecting modest earnings growth in FY27. That means much of the upside would need to come from investors becoming willing to pay a higher multiple for those earnings.

For that to happen, I think CSL would need to show clear progress in Behring, fewer problems elsewhere in the portfolio, and a credible path back to stronger earnings growth.

Foolish Takeaway

I would not rule out CSL shares reaching $200 in 2027, but I think plenty would need to go right for it to happen that quickly.

A forward earnings multiple of around 24 times is certainly achievable for a company of CSL's quality if confidence returns.

My expectation would be for the recovery to take a little longer. If CSL keeps making progress through FY27, I think $200 could become a much more realistic target heading into 2028.